1. Home
  2. TOL vs VTRS Comparison

TOL vs VTRS Comparison

Compare TOL & VTRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Toll Brothers Inc.

TOL

Toll Brothers Inc.

HOLD

Current Price

$140.30

Market Cap

13.8B

ML Signal

HOLD

Logo Viatris Inc.

VTRS

Viatris Inc.

HOLD

Current Price

$11.65

Market Cap

12.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TOL
VTRS
Founded
1967
1961
Country
United States
United States
Employees
N/A
N/A
Industry
Homebuilding
Medicinal Chemicals and Botanical Products
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
13.8B
12.0B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
TOL
VTRS
Price
$140.30
$11.65
Analyst Decision
Buy
Hold
Analyst Count
15
6
Target Price
$150.73
$11.50
AVG Volume (30 Days)
1.3M
7.4M
Earning Date
12-08-2025
11-06-2025
Dividend Yield
0.72%
4.12%
EPS Growth
N/A
N/A
EPS
13.49
N/A
Revenue
$10,966,723,000.00
$14,124,400,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$3.78
$1.16
P/E Ratio
$10.32
N/A
Revenue Growth
1.11
N/A
52 Week Low
$86.67
$6.85
52 Week High
$149.79
$13.13

Technical Indicators

Market Signals
Indicator
TOL
VTRS
Relative Strength Index (RSI) 57.75 73.17
Support Level $138.36 $10.67
Resistance Level $141.58 $11.63
Average True Range (ATR) 4.10 0.25
MACD 0.31 0.09
Stochastic Oscillator 75.31 88.43

Price Performance

Historical Comparison
TOL
VTRS

About TOL Toll Brothers Inc.

Toll Brothers is the leading luxury homebuilder in the United States with an average sale price well above public competitors'. The company operates in over 60 markets across 24 states and caters to move-up, active-adult, and second-homebuyers. Traditional homebuilding operations represent most of company's revenue. Toll Brothers also builds luxury for-sale and for-rent properties in urban centers across the US. It has its headquarters in Horsham, Pennsylvania.

About VTRS Viatris Inc.

Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.

Share on Social Networks: